SUBSCRIBE: Print / eNewsletter
FDA Approves Front-Line Lenalidomide for Multiple Myeloma
The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.
RCC Drug Axitinib Could Treat TKI-Resistant CML
Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.
Omacetaxine Effective for Intolerant/Resistant CML
In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.
FDA Approves Ibrutinib for Waldenström Macroglobulinemia
The FDA has expanded the approved use of ibrutinib (Imbruvica) to include patients with Waldenström macroglobulinemia, a rare type of non-Hodgkin lymphoma.
ASCO Names CLL Therapies “Cancer Advance of the Year”
In its Annual Report on Progress Against Cancer, ASCO has declared that the transformation in the treatment of patients with CLL is the “advance of the year.”
INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Ponatinib Shows Promise in CML Even After Early Trial Termination
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
Higher Bortezomib Dose Upped Multiple Myeloma Survival
A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.
Recently Approved ALL Drug Gets Big Price Tag
According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.
Daratumumab Safe With Myeloma Backbone Therapies
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.